00000000nam 2200000za 4500
0019.847509
003CaOODSP
00520221107153446
007cr |||||||||||
008171121s2018    onc     o    f000 0 eng d
020 |a9780660239293|z9780660239309
040 |aCaOODSP|beng
043 |an-cn---
0861 |aNR16-172/2017E-PDF
24500|aSynthetic archaeosome adjuvants for improved vaccine formulation (L-11784) |h[electronic resource].
260 |a[Ottawa] : |bNational Research Council Canada, |c[2018]
300 |a[1] p.
500 |aIssued also in French under title: Adjuvants d’archéosomes synthétiques pour améliorer la préparation de vaccins (L-11784).
500 |aCaption title.
500 |a"January 2017."
520 |a“Vaccine adjuvants are immune stimulating compounds that, when combined with antigens, enhance the magnitude, the quality and/or the duration of immune responses. Though adjuvants play a central role in vaccination, few non-toxic adjuvants are currently available to vaccine developers. To address this need, the NRC has developed synthetic archaeal lipids for the production of well-defined, tailor-made, non-toxic and thermostable adjuvants that can be can combined with a wide range of antigens. The NRC’s synthetic archaeosomes have both immunomodulating and antigen-delivery adjuvant properties. They can be customized to evoke specific immune responses that are long and durable”--Highlights.
530 |aIssued also in print format.
693 4|aImmunological adjuvants
693 4|aLiposomes
7102 |aNational Research Council Canada.
77508|tAdjuvants d’archéosomes synthétiques pour améliorer la préparation de vaccins (L-11784) |w(CaOODSP)9.847512
7760#|tSynthetic archaeosome adjuvants for improved vaccine formulation |w(CaOODSP)9.847511
85640|qPDF|s116 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-172-2017-eng.pdf